Advertisement

Overige stimulerende middelen

  • Raymond Niesink

‘Gebrek aan energie, moe en lusteloos’, we hebben er allemaal wel eens mee te maken. Op zich niet zo'n probleem, maar het overvalt ons op het moment dat we de volgende dag een tentamen moeten doen, tegen de deadline voor een artikel aanhikken, of nog een hele nachtdienst voor de boeg hebben. De een lost het op door even fl ink te gaan sporten, douchen en voilà. De ander neemt één of enkele koppen koffie en sleept zich er zo doorheen. Natuurlijk zijn er ook mensen die op zo'n moment grijpen naar xtc, cocaïne of amfetamine, verboden stimulerende middelen, zoals die in de vorige hoofdstukken ter sprake zijn gekomen. Als we de reclamefolders van fabrikanten van voedingssupplementen mogen geloven, zijn er ook middelen waaraan minder risico's kleven dan aan de verboden stimulerende middelen, legaal zijn, en toch wonderen verrichten. In dit hoofdstuk bespreken we een aantal stimulerende middelen die, in de meeste gevallen, legaal verkrijgbaar zijn en veelal als voedingssupplementen aan de man worden gebracht.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Referenties

  1. Akaoka H, Roussel B, Lin JS, Chouvet G, Jouvet M. Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity. Neurosci Lett 1991; 123: 20–22.PubMedCrossRefGoogle Scholar
  2. Al-Motarreb A, Baker K, Broadley KJ. Khat: pharmacological and medical aspects and its social use in Yemen. Phytother Res 2002; 16, 403–413.PubMedCrossRefGoogle Scholar
  3. Ballon JS, Feifel D. A systematic review of modafinil: Potential clinical uses and mechanisms of action. Journ Clin Psychiatry 2006; 67: 554–556.CrossRefGoogle Scholar
  4. Banerjee D, Vitiello MV, Grunstein RR. Pharmacotherapy for excessive daytime sleepiness. Sleep Med Rev 2004; 8: 339–354.PubMedCrossRefGoogle Scholar
  5. Barendregt B, Boon B. Ephedragebruikers in Nederland: plezier, presteren en afslanken, (vol. 38). Rotterdam: IVO; 2005.Google Scholar
  6. Beltman W, Riel AJPH van, Wijnands-Kleukers APG, Vriesman MF, Hengel-Koot IS Van Den, Vries I de, Meulenbelt J. Smartshops: Overzicht van producten, geclaimde werking en hun medisch-toxicologische relevantie. Bilthoven: RIVM; 1999.Google Scholar
  7. Beusterien KM, Rogers AE, Walsleben JA, Emsellem HA, Reblando JA, Wang L. et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999; 22: 757–765.PubMedGoogle Scholar
  8. CAM. Risicoschatting Qat 2007. Risicoschattingsrapport. Bilthoven: RIVM; 2007.Google Scholar
  9. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000; 75: 711–721.PubMedCrossRefGoogle Scholar
  10. Chan EL, Ahmed TM, Wang M, Chan JC. History of medicine and nephrology in Asia. Am Journ Nephrol 1994; 14: 295–301.CrossRefGoogle Scholar
  11. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005; 30: 205–211.PubMedCrossRefGoogle Scholar
  12. Degraeve G. Khat-induced psychosis? Tijdschr Psychiatr 2007; 49: 763–767.PubMedGoogle Scholar
  13. Engber TM, Dennis SA, Jones BE, Miller MS, Contreras PC. Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine. Neuroscience 1998; 87: 905–911.PubMedCrossRefGoogle Scholar
  14. Gahlinger PM. Illegal drugs: a complete guide to their history, chemistry, use and abuse. Sagebrush Press: 203–22.Google Scholar
  15. Geisshusler S, Brenneisen R. The content of psychoactive phenylpropyl and phenylpentenyl khatamines in Catha edulis Forsk. of different origin. J Ethnopharmacol 1987; 19: 269–277.PubMedCrossRefGoogle Scholar
  16. Greenway FL, De JL, Blanchard D, Frisard M, Smith SR. Effect of a dietary herbal supplement containing caffeine and ephedra on weight, metabolic rate, and body composition. Obes Res 2004; 12: 1152–1157.PubMedCrossRefGoogle Scholar
  17. Groot VAIC de. Diagnostiseren, behandelen en leven met narcolepsie: een autoimmuunziekte die het hypocretine systeem selecties afbreekt. (Internet rapport:): 2007.Google Scholar
  18. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343: 1833–1838.PubMedCrossRefGoogle Scholar
  19. Hanson G, Venturelli P. Drugs and society. 6th ed. Ontario: Jones and Bartlett Publishers; 2001.Google Scholar
  20. Hassan NA, Gunaid AA, El Khally FM, Murray-Lyon IM. The effect of chewing Khat leaves on human mood. Saudi Med J 2002; 23: 850–853.PubMedGoogle Scholar
  21. Hellriegel ET, Arora S, Nelson M, Robertson P. Steady-state pharmacokinetics and tolerability of modafinil given alone or in combination with methylphenidate in healthy volunteers. J Clin Pharmacol 2001; 41: 895–904.PubMedCrossRefGoogle Scholar
  22. Hellriegel ET, Arora S, Nelson M, Robertson P. Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers. J Clin Pharmacol 2002; 42: 450–460.PubMedCrossRefGoogle Scholar
  23. Illy E. The complexity of coffee. Sci Am 2002: 72–7.Google Scholar
  24. Ishizuka T, Murakami M, Yamatodani A. Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats. Eur J Pharmacol 2007.Google Scholar
  25. Ishizuka T, Sakamoto Y, Sakurai T, Yamatodani A. modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett 2003 339: 143–146.PubMedCrossRefGoogle Scholar
  26. Ivanenko A, Tauman R, Gozal D. modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 2003; 4: 579–82.PubMedCrossRefGoogle Scholar
  27. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000; 14: 53–60.PubMedCrossRefGoogle Scholar
  28. Jasinski DR, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 2000; 23: 149–156.PubMedCrossRefGoogle Scholar
  29. Juliano LM, Griffiths RR. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl) 2004; 176: 1–29.CrossRefGoogle Scholar
  30. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 1997; 68: 2032–2037.PubMedCrossRefGoogle Scholar
  31. Landi MT, Sinha R, Lang NP, Kadlubar FF. Human cytochrome P4501A2. IARC Sci Publ 1999; 173–95.Google Scholar
  32. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Nat Acad Sci USA 1996; 93, 14128–14133.PubMedCrossRefGoogle Scholar
  33. Littner M, Johnson SF, McCall WV, Anderson WM, Davila D, Hartse SK. et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001; 24: 451–66.PubMedGoogle Scholar
  34. Maisto SA, Galizio M, Connors GJ. Drug use and abuse. Belmont: Thomson Wadsworth; 2004.Google Scholar
  35. Malcolm R, Book SW, Moak D, DeVane L, Czepowicz V. Clinical applications of modafinil in stimulant abusers: low abuse potential. Am J Addict 2002; 11: 247–249.PubMedCrossRefGoogle Scholar
  36. Mehendale SR, Bauer BA, Yuan CS. Ephedra-containing dietary supplements in the US versus ephedra as a Chinese medicine. Am J Chin Med 2004; 32: 1–10.PubMedCrossRefGoogle Scholar
  37. Mehta MA, Sahakian BJ, Robbins TW. Comparative psychopharmacology and methylphenidate and related drugs in human volunteers, patients with ADHD and experimental animals. In: Solanto MV, Arnstein AFT, Castellanos FX. Stimulant Drugs and ADHD. Oxford: Oxford University Press; 2001: 303–331.Google Scholar
  38. Mitler MM, Harsh J, Hirshkowitz M, Guilleminault C. Long-term efficacy and safety of modafinil (PROVIGIL(R)) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med 2000; 1: 231–233.PubMedCrossRefGoogle Scholar
  39. Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med 2000; 1: 109–116.PubMedCrossRefGoogle Scholar
  40. Nasr AH, Khatri ML. Head and neck squamous cell carcinoma in Hajjah, Yemen. Saudi Med J 2000; 21: 565–568.PubMedGoogle Scholar
  41. Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Addit Contam 2003; 20: 1–30.CrossRefGoogle Scholar
  42. Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 1992; 17: 139–170.PubMedCrossRefGoogle Scholar
  43. Nencini P, Ahmed AM. Khat consumption: a pharmacological review. Drug Alcohol Depend 1989; 23: 19–29.PubMedCrossRefGoogle Scholar
  44. Nencini P, Ahmed AM, Elmi AS. Subjective effects of khat chewing in humans. Drug Alcohol Depend 1986; 18: 97–105.PubMedCrossRefGoogle Scholar
  45. Nishino S, Okura M, Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Review Article. Sleep Med Rev 2000; 4: 57–99.CrossRefGoogle Scholar
  46. Novak SP, Ball JK. Emergency department visits involving ADHD stimulant medications. The New Dawn report 2006; 1–4.Google Scholar
  47. Pennings EJM. Assessment of khat (Catha edulis Forsk). ECDD 2006; 34.Google Scholar
  48. Robertson P, DeCory HH, Madan A, Parkinson A. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 2000; 28: 664–671.PubMedGoogle Scholar
  49. Robertson P, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003; 42: 123–137.PubMedCrossRefGoogle Scholar
  50. Rogers AE, Aldrich MS, Berrios AM, Rosenberg RS. Compliance with stimulant medications in patients with narcolepsy. Sleep 1997; 20: 28–33.PubMedGoogle Scholar
  51. Satel S. Is caffeine addictive? - a review of the literature. Am J Drug Alcohol Abuse 2006; 32: 493–502.PubMedCrossRefGoogle Scholar
  52. Sahakian B, Morein-Zamir S. ‘Professor's little helper’. Nature 2007; 450: 1157–1159.PubMedCrossRefGoogle Scholar
  53. Santen H van. modafinil: de nieuwe zwarte koffie. NRC-Handelsblad: 22 december 2007.Google Scholar
  54. Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS. et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000; 20: 8620–8628.PubMedGoogle Scholar
  55. Schulman S. Addressing the potential risks associated with ephedra use: a review of recent efforts. Public Health Rep 2003; 118: 487–492.PubMedGoogle Scholar
  56. Smith MT, Crouch NR, Gericke N, Hirst M. Psychoactive constituents of the genus Sceletium N.E.Br. and other Mesembryanthemaceae: a review. J Ethnopharmacol 1996; 50: 119–130.PubMedCrossRefGoogle Scholar
  57. Soni MG, Carabin IG, Griffiths JC, Burdock GA. Safety of ephedra: lessons learned. Toxicol Lett 2004; 150: 97–110.PubMedCrossRefGoogle Scholar
  58. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005; 75: 406–433.PubMedCrossRefGoogle Scholar
  59. Swanson JM, Volkow ND. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci Biobehav Rev 2003; 27: 615–621.PubMedCrossRefGoogle Scholar
  60. Toennes SW, Harder S, Schramm M, Niess C, Kauert GF. Pharmacokinetics of cathinone, cathine and norephedrine after the chewing of khat leaves. Br J Clin Pharmacol 2003; 56: 125–130.PubMedCrossRefGoogle Scholar
  61. Toennes SW, Kauert GF. Driving under the infl uence of khat - alkaloid concentrations and observations in forensic cases. Forensic Sci Int 2004; 140: 85–90.PubMedCrossRefGoogle Scholar
  62. US Patent 6,288,104. Pharmaceutical compositions containing mesembrine and related compounds. 2007.Google Scholar
  63. Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU. Pharmacodynamics and pharmacokinetics of khat: a controlled study. Clin PharmacolTher 1994; 55: 556–562.Google Scholar
  64. Wigal SB, McGough JJ, McCracken JT, Biederman J, Spencer TJ, Posner KL. et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005; 9: 275–289.PubMedCrossRefGoogle Scholar
  65. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111: 179–185.PubMedCrossRefGoogle Scholar
  66. Wills S. Drugs of abuse. 1st ed. Londen: The pharmaceutical press; 1997.Google Scholar
  67. Wolffers I. Tien jaar Ritalin geen reden voor een feestje. Dagblad De Pers: Juli 2007.Google Scholar
  68. Wong YN, King SP, Laughton WB, McCormick GC, Grebow PE. Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol 1998a; 38: 276–282.Google Scholar
  69. Wong YN, King SP, Simcoe D, Gorman S, Laughton W, McCormick GC. et al. Openlabel, single-dose pharmacokinetic study of modafinil tablets: infl uence of age and gender in normal subjects. J Clin Pharmacol 1999; 39: 281–288.PubMedGoogle Scholar
  70. Wong YN, Wang L, Hartman L, Simcoe D, Chen Y, Laughton W. et al. Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers. J Clin Pharmacol 1998b; 38: 971–978.Google Scholar
  71. Yousef G, Huq Z, Lambert T. Khat chewing as a cause of psychosis. Br J Hosp Med 1995; 54: 322–326.PubMedGoogle Scholar

Websites

  1. Azarius: Sceletium tortuosum (Kanna). azarius.net/smartshop/energy/spacy .
  2. Azarius: Smart en headshop. azarius.net/encyclopedia/54 .Laatst geraadpl 25 nov 2007.
  3. Kannashop website: thekannashop.com . Laatst geraadpl 25 nov 2007.
  4. Sceletium.org . Laatst geraadpl 25 nov 2007.
  5. Unityugs.drnl/index . Laatst geraadpl 25 nov 2007.

Copyright information

© Bohn Stafleu van Loghum 2008

Authors and Affiliations

  • Raymond Niesink

There are no affiliations available

Personalised recommendations